Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226392 | 0.94 | CHRM3 (0.47) | CHRM3NPC1RAB9AL3MBTL1CHRM2 | |
| SCHEMBL14512374 | 0.90 | NPC1 (0.43) | CHRM3NPC1RAB9ALMNAMAPT | |
| SCHEMBL303047 | 0.90 | CHRM3 (0.51) | CHRM3TAS1R3TAS1R1TAS1R2CHRM2 | |
| SCHEMBL29688317 | 0.90 | CHRM3 (0.51) | CHRM3TAS1R3TAS1R1TAS1R2CHRM2 | |
| SCHEMBL14065946 | 0.86 | CHRM3 (0.46) | CHRM3NPC1RAB9ALMNAMAPT | |
| SCHEMBL5564889 | 0.85 | CHRM3 (0.47) | CHRM3CHRM2CHRM1ALOX15 | |
| SCHEMBL20986957 | 0.83 | LMNA (0.47) | CHRM3LMNAMAPT | |
| SCHEMBL29349968 | 0.83 | CHRM3 (0.51) | CHRM3LMNACHRM2CHRM1ALOX15 | |
| SCHEMBL68043 | 0.83 | CHRM3 (0.51) | CHRM3LMNACHRM2CHRM1ALOX15 | |
| SCHEMBL29445383 | 0.83 | CHRM3 (0.51) | CHRM3LMNACHRM2CHRM1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069398-A1 | Pyrazolyl Carboxamides | BAYER CROPSCIENCE AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069398-A1 | Pyrazolyl Carboxamides | BAYER CROPSCIENCE AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069398-A1 | Pyrazolyl Carboxamides | BAYER CROPSCIENCE AG (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2007068370-A2 | PYRAZOLYL CARBOXAMIDES | BAYER CROPSCIENCE AG (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069398-A1 | Pyrazolyl Carboxamides | MRPL21, AADAC, PGLS | CHRM3 2776/4885NPC1 3869/4885RAB9A 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.